| Literature DB >> 32005658 |
Xiaotian Zhong1, Srinath Jagarlapudi2, Yan Weng3, Mellisa Ly4, Jason C Rouse4, Kim McClure2, Tetsuya Ishino3, Yan Zhang3, Eric Sousa3, Justin Cohen3, Boriana Tzvetkova4, Kaffa Cote4, John J Scarcelli5, Keith Johnson4, Joe Palandra3, James R Apgar3, Suma Yaddanapudi2, Romer A Gonzalez-Villalobos2, Alan C Opsahl2, Khetemenee Lam3, Qing Yao3, Weili Duan3, Annette Sievers3, Jing Zhou3, Darren Ferguson3, Aaron D'Antona3, Richard Zollner3, Hongli L Zhu3, Ron Kriz3, Laura Lin3, Valerie Clerin6.
Abstract
The fortuitously discovered antiaging membrane protein αKlotho (Klotho) is highly expressed in the kidney, and deletion of the Klotho gene in mice causes a phenotype strikingly similar to that of chronic kidney disease (CKD). Klotho functions as a co-receptor for fibroblast growth factor 23 (FGF23) signaling, whereas its shed extracellular domain, soluble Klotho (sKlotho), carrying glycosidase activity, is a humoral factor that regulates renal health. Low sKlotho in CKD is associated with disease progression, and sKlotho supplementation has emerged as a potential therapeutic strategy for managing CKD. Here, we explored the structure-function relationship and post-translational modifications of sKlotho variants to guide the future design of sKlotho-based therapeutics. Chinese hamster ovary (CHO)- and human embryonic kidney (HEK)-derived WT sKlotho proteins had varied activities in FGF23 co-receptor and β-glucuronidase assays in vitro and distinct properties in vivo Sialidase treatment of heavily sialylated CHO-sKlotho increased its co-receptor activity 3-fold, yet it remained less active than hyposialylated HEK-sKlotho. MS and glycopeptide-mapping analyses revealed that HEK-sKlotho is uniquely modified with an unusual N-glycan structure consisting of N,N'-di-N-acetyllactose diamine at multiple N-linked sites, one of which at Asn-126 was adjacent to a putative GalNAc transfer motif. Site-directed mutagenesis and structural modeling analyses directly implicated N-glycans in Klotho's protein folding and function. Moreover, the introduction of two catalytic glutamate residues conserved across glycosidases into sKlotho enhanced its glucuronidase activity but decreased its FGF23 co-receptor activity, suggesting that these two functions might be structurally divergent. These findings open up opportunities for rational engineering of pharmacologically enhanced sKlotho therapeutics for managing kidney disease.Entities:
Keywords: Klotho; LacdiNAc; acute kidney injury; fibroblast growth factor receptor (FGFR); glycosidase; glycosylation; mammalian cell expression; pharmacokinetics; sialic acid; signal transduction
Mesh:
Substances:
Year: 2020 PMID: 32005658 PMCID: PMC7062171 DOI: 10.1074/jbc.RA119.012144
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157